Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets

被引:12
|
作者
Gao, Zongming [1 ]
Ngo, Cindy [1 ]
Ye, Wei [1 ]
Rodriguez, Jason D. [1 ]
Keire, David [1 ]
Sun, Dajun [2 ]
Wen, Hong [2 ]
Jiang, Wenlei [2 ]
机构
[1] US FDA, Div Pharmaceut Anal, Ctr Drug Evaluat & Res, St Louis, MO 63110 USA
[2] US FDA, Off Res & Stand, Off Gener Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
关键词
dissolution; controlled release; osmotic pump(s); gastrointestinal tract; US Pharmacopeia (USP); polymeric drug delivery system(s); physiological model(s); pH; oral drug delivery; in vitro model(s); FOOD; FORMULATION; ABSORPTION; DELIVERY; CLASSIFICATION;
D O I
10.1016/j.xphs.2018.10.014
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In contrast to nifedipine matrix-based extended-release dosage forms, the osmotic pump drug delivery systems have a zero-order drug release independent of external variables such as pH, agitation rate, and dissolution media. The objective of this study focuses on the in vitro evaluation of the mechanical properties of osmotic pump and polymer matrix-based formulations in dissolution media, and the potential impacts that media pH and simulated gastrointestinal contraction have on drug release. Two strengths of osmotic pump product A and polymer matrix-based product B were used in this study. An in-house system was developed with the capability of applying mechanical compression and monitoring mechanical properties of sample during dissolution testing. A United States Pharmacopeia or an in-house apparatus was used for dissolution testing under various conditions. Compared to the product A, the mechanical properties of the product B change significantly at various pHs and mechanical compressions. The results suggest that polymer matrix-based products bear a risk of formulation-related interactions with the gastrointestinal tract during in vivo drug dissolution, especially in the case of concomitant pH and gastric contractile changes. Modified dissolution testing devices may help formulation scientists in product development and provide regulatory agencies with an additional metric for quality assurance of drug products. Published by Elsevier Inc. on behalf of the American Pharmacists Association.
引用
收藏
页码:1189 / 1194
页数:6
相关论文
共 50 条
  • [31] In Vitro-In Vivo Predictive Dissolution-Permeation-Absorption Dynamics of Highly Permeable Drug Extended-Release Tablets via Drug Dissolution/Absorption Simulating System and pH Alteration
    Zi-qiang Li
    Shuang Tian
    Hui Gu
    Zeng-guang Wu
    Makafui Nyagblordzro
    Guo Feng
    Xin He
    AAPS PharmSciTech, 2018, 19 : 1882 - 1893
  • [32] Comparison of gastrointestinal effects with extended-release formulations of oxybutynin and tolterodine
    Peters, KM
    JOURNAL OF UROLOGY, 2004, 171 (04): : 136 - 136
  • [33] A Raman imaging-based technique to assess HPMC substituent contents and their effects on the drug release of commercial extended-release tablets
    Chang, Yan
    Hu, Changqin
    Yang, Rui
    He, Dongsheng
    Wang, Xueyi
    Ning, Baoming
    Sun, Huimin
    Xiong, Yerong
    Tu, Jiasheng
    Sun, Chunmeng
    CARBOHYDRATE POLYMERS, 2020, 244
  • [34] Administration of crushed extended-release pentoxifylline tablets: Bioavailability and adverse effects
    Cleary, JD
    Evans, PC
    Hikal, AH
    Chapman, SW
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (15) : 1529 - 1534
  • [35] Investigation of the Dissolution Characteristics of Nifedipine Extended-Release Formulations Using USP Apparatus 2 and a Novel Dissolution Apparatus
    Garbacz, Grzegorz
    Blume, Henning
    Weitschies, Werner
    DISSOLUTION TECHNOLOGIES, 2009, 16 (02): : 7 - 13
  • [36] Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests
    Ikeuchi, Satomi Yamaguchi
    Kambayashi, Atsushi
    Kojima, Hiroyuki
    Oku, Naoto
    Asai, Tomohiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2018, 41 (11) : 1708 - 1715
  • [37] Effect of pH on drug release from polysaccharide tablets
    Park, HY
    Choi, CR
    Kim, JH
    Kim, WS
    DRUG DELIVERY, 1998, 5 (01) : 13 - 18
  • [38] The effect of HPMC particle size on the drug release rate and the percolation threshold in extended-release mini-tablets
    Mohamed, Faiezah A. A.
    Roberts, Matthew
    Seton, Linda
    Ford, James L.
    Levina, Marina
    Rajabi-Siahboomi, Ali R.
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2015, 41 (01) : 70 - 78
  • [39] An In Vitro Dissolution Method for Testing Extended-Release Tablets Under Mechanical Compression and Sample Friction
    Gao, Zongming
    Cao, Leo N. Y.
    Liu, Xiaofei
    Tian, Li
    Rodriguez, Jason D.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 111 (06) : 1652 - 1658
  • [40] Converting from incoming opioids to oxycodone extended-release (OXYCR) tablets or oxycodone/naloxone extended-release (OXN) tablets - an analysis of the experience from 5 controlled clinical trials
    Steiner, D.
    Moline, M.
    Munera, C.
    Berger, B.
    JOURNAL OF PAIN, 2014, 15 (04): : S89 - S89